作者
Peter W Horby, Marion Mafham, Jennifer L Bell, Louise Linsell, Natalie Staplin, Jonathan Emberson, Adrian Palfreeman, Jason Raw, Einas Elmahi, Benjamin Prudon, Christopher Green, Simon Carley, David Chadwick, Matthew Davies, Matthew P Wise, J Kenneth Baillie, Lucy C Chappell, Saul N Faust, Thomas Jaki, Katie Jefferey, Wei Shen Lim, Alan Montgomery, Kathryn Rowan, Edmund Juszczak, Richard Haynes, Martin J Landray
发表日期
2020/10/24
期刊
The Lancet
卷号
396
期号
10259
页码范围
1345-1352
出版商
Elsevier
简介
Background
Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19.
Methods
In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus lopinavir–ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple (unstratified) randomisation with …
学术搜索中的文章
PW Horby, M Mafham, JL Bell, L Linsell, N Staplin… - The Lancet, 2020